The Avastin® biosimilars market rootsanalysis.com

james hebrew 1 year ago in Health

Roots Analysis has announced the addition of the “Avastin® (Bevacizumab) Biosimilars – Pipeline Review and Partnerships” report to its list of offerings.   Biosimilars of bevacizumab are currently approved / being developed to treat colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer. Experts believe that a strong biosimilar portfolio is equivalent to a blockbuster product, at least for companies…